ArticleJournal of molecular histology2026
Dual action of baicalin against renal fibrosis in hyperuricemic nephropathy: targeting PANX1-P2Y6 signaling and gut microbiota dysbiosis.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemic nephropathy (HN) is accompanied by persistent hyperuricemia, progressive renal injury, and fibrosis, but effective treatment for the fibrotic component remains limited. Baicalin (BA), a flavonoid isolated from Scutellaria baicalensis Georgi, has been reported to have anti-inflammatory and antioxidant effects, although its role in HN-associated renal fibrosis has not been fully defined. In this study, HN was induced in mice with yeast extract and potassium oxonate, followed by BA treatment. Transcriptomic analysis, molecular docking, molecular dynamics simulation, Western blotting, RT-qPCR, and 16S rRNA sequencing were used to investigate the renal effects of BA and the pathways involved. BA treatment reduced serum uric acid (UA), blood urea nitrogen, and creatinine levels and improved renal histological changes. Fibrotic lesions were also alleviated. At the molecular level, BA decreased transforming growth factor beta 1 (TGF-β1) expression and phosphorylated SMAD family member 3 (p-SMAD3)/SMAD family member 3 (SMAD3) ratio, while pannexin 1/P2Y purinergic receptor 6 (PANX1/P2Y6) signaling and cysteine-aspartic protease 3 (Caspase-3) activation were suppressed. Changes were also observed in the intestinal microbiota, with increased abundance of Lactobacillus and Bacteroides after BA administration. Docking and molecular dynamics analyses further showed favorable and stable interactions of BA with PANX1, TGF-β1, SMAD3, and Caspase-3. These findings suggest that the renal protective effect of BA in HN correlates with inhibition of PANX1/P2Y6-related fibrotic signaling and amelioration of gut microbial dysbiosis, suggesting BA as a potential candidate for reducing hyperuricemia-induced renal injury and fibrosis.
Indexed as
Identifiers
42831993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.